ND095

ND095 is a multispecific antibody candidate being developed by Numab Therapeutics for the treatment of central nervous system (CNS) disorders. The molecule is engineered using Numab's proprietary MATCH™ and λ-Cap™ platforms, which enable the development of stable, multi-target biologics. ND095 is designed to simultaneously neutralize multiple complementary disease-inducing pathways, aiming to address CNS indications with a high global disease burden. While the specific molecular targets and the exact clinical development stage have not been publicly disclosed, the program is positioned as a potential first-in-class therapeutic within Numab's internal pipeline.